600750.SHG Jiangzhong Pharmaceutical Co Ltd
- Market cap
- CNY 14.8B
- P/E
- 17.5x
- P/B
- 3.94x
- ROE
- 21.8%
- Dividend yield
- 5.27%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600750.SHG undervalued?
Graham number600750.SHG trades 74.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jiangzhong Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Jiangzhong Pharmaceutical Co Ltd yet.
Jiangzhong Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jiangzhong Pharmaceutical Co Ltd
China Resources Jiangzhong Pharmaceutical Co.,Ltd engages in the manufacture of pharmaceutical products in China. The company offers OTC products, including stomach-strengthening and digestion-promoting tablets, lactobacillus tablets, triple live bifidobacterium enteric-coated capsules, compound fresh bamboo juice liquid, compound coral lozenges, multivitamin tablets, fritillaria and loquat capsules, bezoar and snake gallbladder fritillaria liquid, and compound gold melon se…
Full company profileJiangzhong Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jiangzhong Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.55B | 1.75B | 1.76B | 2.45B | 2.44B | 2.87B | 3.89B | 4.55B | 4.44B | 4.22B | 3.55B |
| Gross Profit | 1.10B | 1.21B | 1.18B | 1.63B | 1.59B | 1.85B | 2.50B | 2.91B | 2.80B | 2.76B | 2.33B |
| Operating Income | 446M | 483M | 548M | 568M | 574M | 626M | 748M | 913M | 1.03B | 1.02B | 975M |
| EBITDA | 506M | 536M | 621M | 679M | 694M | 742M | 878M | 1.05B | 1.16B | 1.17B | 1.09B |
| Net Income | 380M | 418M | 470M | 464M | 474M | 506M | 598M | 719M | 788M | 906M | 823M |
| EPS | 0.62 | 0.66 | 0.75 | 0.74 | 0.75 | 0.80 | 0.95 | 1.00 | 1.25 | 1.43 | 1.30 |
| Balance Sheet | |||||||||||
| Total Assets | 3.07B | 3.36B | 3.82B | 4.76B | 4.92B | 6.00B | 6.28B | 6.40B | 6.51B | 6.88B | 6.63B |
| Total Liabilities | 450M | 449M | 564M | 835M | 672M | 1.42B | 1.77B | 1.77B | 2.04B | 2.18B | 2.13B |
| Shareholders' Equity | 2.62B | 2.92B | 3.25B | 3.56B | 3.88B | 4.00B | 3.89B | 3.91B | 3.86B | 4.02B | 3.77B |
| Cash & Short-term Investments | 898M | 725M | 1.01B | 1.58B | 2.08B | 2.77B | 2.74B | 1.38B | 1.02B | 804M | 283M |
| Total Debt | 30.0M | 70.0M | 20.0M | - | 297K | 4.49M | 90.3M | 57.7M | 109K | 355M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 698M | 125M | 486M | 641M | 753M | 917M | 1.02B | 1.04B | 786M | 971M | - |
| Capital Expenditure | 70.1M | 181M | 121M | 76.3M | 183M | 188M | 346M | 209M | 291M | 281M | 202M |
| Free Cash Flow | 628M | -56.3M | 365M | 565M | 570M | 729M | 676M | 828M | 495M | 690M | 1.13B |
| Ratios | |||||||||||
| ROE | 14.5% | 14.3% | 14.5% | 13.0% | 12.2% | 12.6% | 15.4% | 18.4% | 20.4% | 22.5% | 21.8% |
| ROA | 12.4% | 12.4% | 12.3% | 9.7% | 9.6% | 8.4% | 9.5% | 11.2% | 12.1% | 13.2% | 12.4% |
| Net Profit Margin | 24.5% | 23.9% | 26.8% | 18.9% | 19.4% | 17.6% | 15.4% | 15.8% | 17.8% | 21.5% | 23.2% |
| Debt to Equity | 0.01x | 0.02x | 0.01x | - | 0.00x | 0.00x | 0.02x | 0.01x | 0.00x | 0.09x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Jiangzhong Pharmaceutical Co Ltd dividends
- Dividend yield
- 5.27%
- Forward dividend
- 1.38 CNY
- Payout ratio
- 85.9%
- Ex-dividend date
- Sep 11, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 778M | 1.23 | 85.9% |
| 2024 | CNY 768M | 1.22 | 97.5% |
| 2023 | CNY 801M | 1.11 | 111.4% |
| 2022 | CNY 733M | 1.16 | 122.5% |
| 2021 | CNY 309M | 0.49 | 61.0% |
| 2020 | CNY 163M | 0.26 | 34.5% |
| 2019 | CNY 147M | 0.23 | 31.7% |
| 2018 | CNY 135M | 0.22 | 28.7% |
| 2017 | CNY 121M | 0.19 | 28.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.2:1 on Jun 12, 2020.
Who owns Jiangzhong Pharmaceutical Co Ltd
- Insiders 45.23%
- Institutions 16.75%
- Public & others 38.01%
- Shares outstanding 636M
- Free float 354M
Jiangzhong Pharmaceutical Co Ltd company profile
- Company name
- Jiangzhong Pharmaceutical Co Ltd
- Ticker
- 600750.SHG
- ISIN
- CNE000000M80
- Exchange
- Shanghai Stock Exchange
- Listed since
- Aug 29, 1996
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 4,352
- Fiscal year end
- December
- Address
- No. 788, Torch Avenue, Nanchang, China, 330096
- Phone
- 86 791 8816 9323
- Website
- jzjt.com
About Jiangzhong Pharmaceutical Co Ltd
China Resources Jiangzhong Pharmaceutical Co.,Ltd engages in the manufacture of pharmaceutical products in China. The company offers OTC products, including stomach-strengthening and digestion-promoting tablets, lactobacillus tablets, triple live bifidobacterium enteric-coated capsules, compound fresh bamboo juice liquid, compound coral lozenges, multivitamin tablets, fritillaria and loquat capsules, bezoar and snake gallbladder fritillaria liquid, and compound gold melon seed. It also provides health consumer and other products, such as nourishing, tonics, rehabilitation nutrition, gastrointestinal health, and liver health products. In addition, the company offers prescription drugs comprising traditional Chinese medicine products, which includes Shenbao capsules, Paishi granules, Huangba Shengmai drink, Bazhen Yimu capsules; chemical medicine products, such as lumbrokinase enteric-coated capsules, Rabeprazole sodium enteric-coated tablets, chloroprocaine hydrochloride, etc.; and medicinal materials which includes codonopsis pilosula. The company was formerly known as Jiang Zhong Pharmaceutical Co.,Ltd and changed its name to China Resources Jiangzhong Pharmaceutical Co.,Ltd in January 2025. China Resources Jiangzhong Pharmaceutical Co.,Ltd was founded in 1996 and is headquartered in Nanchang, China.
Jiangzhong Pharmaceutical Co Ltd management
7- Mr. Yongqian XuCEO & Director · born 1973
- Ms. Weili ZhouAccounting Supervisor · born 1983
- Ms. Yongjing TianSecretary of the Board of Directors · born 1982
- Mr. Yanwei HuangChief Financial Officer · born 1985
- Mr. Xiao Rong LuoDeputy General Manager · born 1977
- Mr. Yan YangDeputy General Manager · born 1977
- Mr. Hai Tang LiDeputy General Manager · born 1980